The Effects of HIPAA\u27s Privacy Rule on Medical Research by Wei, Wesley
Arcadia University
ScholarWorks@Arcadia
Faculty Curated Undergraduate Works Undergraduate Research
12-3-2015
The Effects of HIPAA's Privacy Rule on Medical
Research
Wesley Wei
wwei@arcadia.edu
Arcadia University has made this article openly available. Please share how this access benefits you. Your
story matters. Thank you.
Follow this and additional works at: http://scholarworks.arcadia.edu/undergrad_works
Part of the Business Commons, and the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Undergraduate Research at ScholarWorks@Arcadia. It has been accepted for inclusion in
Faculty Curated Undergraduate Works by an authorized administrator of ScholarWorks@Arcadia. For more information, please contact
gordonl@arcadia.edu.
Recommended Citation
Wei, Wesley, "The Effects of HIPAA's Privacy Rule on Medical Research" (2015). Faculty Curated Undergraduate Works. Paper 33.
http://scholarworks.arcadia.edu/undergrad_works/33
Wesley Wei 
Professor Taylor 
Healthcare Planning and Policy 
3 December 2015 
The Effects of HIPAA’s Privacy Rule on Medical Research 
 The HIPAA Privacy Rule has been instated for over a decade, but a high level of 
ambiguity and confusion still resonates within the medical and scientific research community.  
This has resulted in researchers and healthcare organizations experiencing misinterpretation and 
burdens attempting to remain compliant.  HIPAA’s Privacy Rule, implemented in 2003, required 
covered entities to protect PHI, protected health information, and maintain certain disclosure 
regulations.  Covered entities include health plans, health care clearing houses, and health care 
providers (HIPAA Creating Barriers to Research and Discovery, p. 2).  HIPAA was created to 
place safeguards on patient’s protected health information by granting patients new rights for 
accessing medical records, restricting disclosure of PHI, and establishing new sanctions for 
improper use of PHI.  Research was not a formal consideration of HIPAA; however, there have 
been many negative indirect effects on the research community.   In most cases, researchers are 
not considered covered entities; however, if they are employed or workforce members of a 
covered entity they may have to comply with that entity’s HIPAA privacy policies and 
procedures.  Across the nation, researchers have found the HIPAA Privacy Rule has negatively 
impacted the scope, pace, and cost of research (The HIPAA Privacy Rule, p. 3).  
 Although HIPAA was not originally intended to have effects on research, it has created 
“a web of confusion, misinterpretation, and obstacles that now threaten the research enterprise” 
(HIPAA Creating Barriers to Research and Discovery, p. 2).  The Association of Academic 
Health Centers utilized several focus groups to determine the underlying causes of HIPAA’s 
negative impact on the different aspects of research.  The results revealed HIPAA had very 
confusing and vague writing which led to confusion amongst all facets of research from 
“participants to privacy boards and institutions and even states” (p. 2).  This inherent lack of 
understanding has led to inconsistent interpretations and implementation of HIPAA between 
institutions and states which poses issues for multi-site and interstate research (p.2).  In addition 
to confusing language within the rule, the Privacy Rule creates issues for the non-covered 
portion of a hybrid entity.  Although there exists a great deal of leniency in terms of sharing PHI 
within a covered entity, it becomes much more problematic when attempting to share 
information with researchers or other health professionals not employed by the entity.  “Thus, in 
addition to the hundreds of researchers at institutions that were not covered entities, a significant 
number of researchers at the hybrid entities would not be able to access critical information for 
research purposes” (The HIPAA Privacy Rule, p. 4).   
The Privacy Rule also grants every patient the right to access records of each instance the 
institution disclosed his or her PHI with another institution within a six year period.  HIPAA has 
also added an additional requirement, on top of informed consent, that all participants must sign 
an authorization document permitting the use of his or her PHI for the specific study (The 
HIPAA Privacy Rule, p. 5).  However, Institutional Review Boards (IRBs), according to HIPAA, 
can grant waivers of authorization when a researcher can prove minimal risk to a participant’s 
privacy thereby allowing the researcher to use PHI without gaining authorization from individual 
participants (The HIPAA Privacy Rule, p.6).  Although each of these additional safeguards seem 
beneficial to the patients/participants and their security, they impose a “clunky” process on 
researchers and institutions which results in less benefits for the public in the long-run.  
Therefore, despite the advancements the Privacy Rule has created for patient privacy, changes 
must be made to ensure research of future treatments is protected. 
HIPAA’s implementation has provided many benefits to patients and research 
participants.  The Privacy Rule allows patients to determine and authorize the institutions or 
entities with whom their PHI can be disclosed.  HIPAA has increased the safeguards for patient 
information and pushed forth the need for more patient knowledge about treatments and research 
they are participating in.  In addition to informed consent, HIPAA requires patients to sign an 
authorization document.  This document provides the patient with further control of the use and 
disclosure of his or her PHI by allowing them to determine specific studies in which their 
information can be used.  Concurrently, the Privacy Rule allows research participants to revoke 
the authorization at any point during the study, preventing the entity from disclosing any non-
disclosed or unused information (Clinical Research and the HIPAA Privacy Rule, p. 2-3).   
Furthermore, the Rule allows patients to request records of all instances within the past six years 
of when their PHI was used or disclosed (The HIPAA Privacy Rule, p.4).  Overall, the HIPAA 
Privacy Rule has been beneficial in providing security and control for patients and research 
participants. 
Despite the benefits patients receive through the HIPAA Privacy Rule, there are many 
more negative consequences that the entire research enterprise experiences.  Research 
institutions face issues attempting to comply with different requirements of the Privacy Rule.  
Amongst the research community, “the greatest concern was expressed about the negative 
impact on the costs of research” (The HIPAA Privacy Rule, p. 3).  In order to stay compliant 
with the requirement “Accounting for Disclosures,” institutions have to “maintain large 
quantities of detailed information on every patient and research participant and have it readily 
and easily accessible to fulfill requests at any time” (The HIPAA Privacy Rule, p. 5).  
Maintaining this information, despite the lack of actual requests, has increased expenditure and 
staff and caused changes in organizational structure (p. 5).  According to the Association of 
Academic Health Centers, the increased costs and changes will prove troublesome in times of 
“fiscal constraint when institutions must be sure that resources are allocated and used in the most 
effective fashion and applied to the conduct of essential research” (p.5).  Institutional Review 
Boards, which are responsible for evaluating research protocol and assessing its effects on the 
health, safety, and privacy of research participants, are also negatively impacted by the Privacy 
Rule.  Since its implementation, many institutions have placed additional responsibilities on their 
IRBs.  A survey taken by the AAHC found approximately 76.6% of respondents had their IRBs 
assume additional roles to manage the different aspects of the Privacy Rule.  Out of the 76.6%, 
62.3% reported the impact of adding these additional responsibilities to IRB members as 
negative or strongly negative.  Handling the waiver facet of the Privacy Rule has increased the 
workload for IRBs.  The additional workload is caused by the need for additional allotted time in 
IRB meetings to discuss HIPAA issues thereby increasing the process (The HIPAA Privacy 
Rule, p.6).   
In addition, the ambiguity of the HIPAA Privacy Rule has led to misinterpretation 
amongst all parts of the research community.  This leads to not only increased costs, but also 
contributes to a significantly slower pace of research.  One specific example is in terms of multi-
site research.  According to the AAHCA, because of the multiple restrictions the Privacy Rule 
places on covered entities releasing PHI to other institutions, “community partners have been 
reluctant to participate in this research in the face of added administrative hurdles and 
complications… which arise from misinterpretation in the Rule” (The HIPAA Privacy Rule, 
p.8).  Although there are no requirements stating the need for multiple approvals for multi-site 
research, “a lack of clarity in the Privacy Rule, along with its guidance and a fear of liability” has 
led to many institutions utilizing multiple approvals (HIPAA Creating Barriers to Research and 
Discovery, p.3).  These multiple approvals significantly impede the research process.  HIPAA’s 
Privacy Rule has created barriers to research because its vague wording causes confusion which 
has forced decision makers to place more focus and funds on decoding the complex law and less 
on the actual research (HIPAA Creating Barriers to Research and Discovery, p.2). 
The HIPAA Privacy Rule was created in response to concern over abuse of the privacy of 
health information.  The Privacy Rule defines a category of health information, PHI, for which it 
has placed strict disclosure and usage regulations.  Some of the defined permitted disclosures and 
usages are to the individual who is the subject of the information, treatment, payment, and health 
care operations (HIPPA Privacy Summary).  The Rule also defines specific administrative 
policies which covered entities must comply with.  HIPAA also outlines penalties that entities 
can incur for noncompliance.  For civil lawsuits, a covered entity may be fined $100 per failure 
to comply with a requirement and up to $25,000 per year for multiple violations of an identical 
requirement.  For criminal penalties, “a person who knowingly obtains or discloses individually 
identifiable health information…faces a fine of $50,000 and up to one-year imprisonment” 
(HIPPA Privacy Summary)  The penalty then increases to “$100,000 and up to five years 
imprisonment if the wrongful conduct involves false pretenses, and to $250,000 and up to ten 
years imprisonment if the conduct involves the intent to sell, transfer, or use individually 
identifiable health information for commercial advantage, personal gain, or malicious harm” 
(HIPPA Privacy Summary).  Depending on the charge, civil or criminal, the Department of 
Health and Human Services or the Department of Justice, respectively, will enforce compliance. 
Protecting the privacy of patient information is important for patient safety in both 
administrating health care and when using the data for research.  However, the HIPAA Privacy 
Rule has created consequences that have slowed the pace of research and scientific discovery.  In 
addition, institutions have increased expenditures to hire more personnel to maintain compliance.  
The overall approval and conduction time has increased thus increasing the cost of research 
exponentially.  The best way to solve the cost and pace issues is to exempt research from the 
requirements of the HIPAA Privacy Rule and revert back to the previous use of the Common 
Rule with some revisions, which has been adopted by seventeen federal agencies including the 
Department of Health and Human Services.  The Common Rule also provided “requirements to 
ensure that institutions and researchers protect the safety and privacy of human research subjects, 
including the protection of patient information” (The HIPAA Privacy Rule, p. 2).  It also requires 
all research on human subjects, funded or conducted by a federal agency to be approved by an 
IRB and that all subjects provide informed consent prior to participation.  The Common Rule has 
been successful for over thirty years in protecting patient safety and privacy.  The only revision 
necessary to the Common Rule would be to integrate stricter health information privacy 
standards and to revise the protections to adapt to new technologies and threats to patient safety 
and privacy.  Much like the HIPAA Privacy Rule, under the Common Rule, all research 
organizations should create a “common set of procedures…to verify the credentials of and to 
authenticate persons requesting and accessing information through the network” (HIPAA 
Safeguards, p. 2).  The Common Rule should also ensure that research organizations utilize a 
centrally controlled “exchange network, network equipment, and exchange conduits” to make 
sure the process is “protected by a single set of safeguards and security mechanisms.”  These 
revisions will make a more adaptable and strict Common Rule for medical research. 
Even though the HIPPA Privacy Rule has been in place for over a decade, its ambiguity 
and resulting misinterpretations has created barriers to the advancement of scientific and medical 
research in the United States.  The resulting slowed pace of research from vague wording of 
HIPAA has increased costs for research institutions.   By utilizing a revised Common Rule, the 
many issues resulting from misinterpretation of HIPAA will be eliminated.  Avoiding the 
diversion of funds to hiring new personnel will allow the research enterprise to flourish. 
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